This is likely explained by regulation of PD-L1 by USP7 and USP22 in a tumor type–specific manner, since we have shown previously that CRISPR targeted USP22 deletion resulted in PD-L1 downregulation in human breast cancer cells but not in B16 cells (26). This evidence concerns the gene CD274 and neoplasm.